Keywords: Merck & Co, Vytorin, USA, FDA, Kidney disease patients

FDA panel gives unanimous backing for Merck & Co’s Vytorin for some kidney disease patients

Article | 04 November 2011

Print This

US drug giant Merck & Co (NYSE: MRK) said yesterday that the Endocrinologic and Metabolic Drugs Advisory Committee of the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in